Graft-<i>versus</i>-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe idiopathic aplastic anemia (SAA) has improved in recent years, approaching 75% at 5 years. However, an SAA-adapted composite endpoint, graft-versus-host disease (GvHD) and relapse/rejection-free survival (GRFS)...
| Published in: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2023-03-01
|
| Online Access: | https://haematologica.org/article/view/11024 |
